Daily Investing Note (@investing_note) header
Daily Investing Note (@investing_note) profile picture

Documenting my investing journey, sharing research, lessons, mistakes, and simple notes on markets and long-term investing. $NVDA $GOOGL $MSFT $AMD

Joined May 2011
Photo by Daily Investing Note (@investing_note)Photo by Daily Investing Note (@investing_note)Photo by Daily Investing Note (@investing_note)Photo by Daily Investing Note (@investing_note)Photo by Daily Investing Note (@investing_note)Photo by Daily Investing Note (@investing_note)Photo by Daily Investing Note (@investing_note)Photo by Daily Investing Note (@investing_note)Photo by Daily Investing Note (@investing_note)Photo by Daily Investing Note (@investing_note)
Good morning and have a nice week! ☀️ How to Trick Your Brain From Broke to Something (Practical) It is 10:47 p.m. You have spent the last hour watching other people explain how to become financially free. Someone your age has bought another apartment. Someone else says a side hustle changed their life. You save a video about investing, close the app, and remember the budget you were supposed to review tonight. Now, you tell yourself. You are too tired now. Read full article: dailyinvestingnote.substack.…
11
2
19
611
Daily Investing Note retweeted
FDA rejected $CAPR and its down almost -80%
🚨 $CAPR Reminder: The FDA has NOT officially approved Deramiocel yet. Despite the recent hype and stock price surge, approval is still pending. Approval could lead to +50% to +100% otherwise to -50% or more
1
1
209
Could Jensen Huang Return to NVIDIA With NVDA and the broader market facing significant pressure over the past few days, calls for Jensen Huang's return as CEO are growing louder. Investors, employees and influential figures are pushing NVIDIA's board to reconsider. Even President Trump has publicly called for Jensen to be given a second chance, while Jensen himself has expressed openness to returning. Although NVIDIA's board has so far rejected the idea, I believe the mounting pressure could change things quickly. I wouldn't be surprised if we see Jensen return within the next few days or weeks.
1
1
1
70
Yesterday, nearly every corner of the market took a hit. 🔴 Stocks 🔴 Crypto 🔴 Precious metals 🟢 Biotech - one of the few sectors pushing back against the broader market sell-off.
5
1
2
37
FDA rejected $CAPR and its down almost -80%
🚨 $CAPR Reminder: The FDA has NOT officially approved Deramiocel yet. Despite the recent hype and stock price surge, approval is still pending. Approval could lead to +50% to +100% otherwise to -50% or more
1
1
209
Daily Investing Note retweeted
🚨 $CAPR Reminder: The FDA has NOT officially approved Deramiocel yet. Despite the recent hype and stock price surge, approval is still pending. Approval could lead to +50% to +100% otherwise to -50% or more
1
1
480
Today is a Black Friday in the stock market! $NVDA -50% discounted $AMD -30% discounted $GOOG -40% discounted
1
1
87
$ANT – Bad IPO Timing ANT entered the market amid growing AI sector uncertainty. - NVIDIA Under scrutiny over suspected chip smuggling to China and potential interference in a US investigation. - AMD Facing concerns over AI chip exports to China, including military linked firms, amid rising US-China tensions. Anthropic couldn't have picked a worse time for its IPO.
2
2
89
🚨 $CAPR Reminder: The FDA has NOT officially approved Deramiocel yet. Despite the recent hype and stock price surge, approval is still pending. Approval could lead to +50% to +100% otherwise to -50% or more
1
1
480
$AMD key points to understand: The main point of the investigation is that a Chinese company is using AMD technology and has reportedly received recent firmware updates. However, there is still no clear evidence that AMD supplied these updates directly. (So it might be false) The key question remains: how did the company obtain them?
2
2
61
Finally, man’s greatest fear of going bald might be coming to an end... Researchers just developed an experimental electric comb called "Detangle" that achieved nearly 100% hair regrowth in 28 days during lab tests.
1
1
1
32
Anthropic $ANT surged approximately 34% above its IPO price.
1
1
61
$INSM surged following Bloomberg reports that Sanofi is exploring an acquisition and working with advisers. - No official offer or agreement announced yet. - Potential deal could still be weeks away. - Strong takeover catalyst, but deal remains uncertain.
221
The investigation with $AMD related to that a blacklisted Chinese company: IEIT Systems IEIT Systems (Inspur) continued using updated AMD firmware after being placed on the US export blacklist in March 2025. IEIT's contribution to AMD is likely below 10% of total revenue if it purchases directly. Probably even more. If the allegations confirmed, these are the potential US penalties: - 6 potential violations = $2.25M -to $6M - Could face export-license restrictions (This could hurt the most) 🚨
73
It's not just $AMD that's down today. However, AMD's sharp drop appears to be mainly driven by an investigation published at 10:27 AM ET. The report raises concerns about potential US export-control violations involving a blacklisted Chinese server manufacturer, as well as financial risks tied to AMD's AI partnerships and customer commitments. These are allegations, not confirmed violations, but the report has clearly shaken investor confidence.
2
2
109
Raise hands, who is not playing GTA today?
2
2
2
69
The average cost to mine 1 bitcoin:native is approximately $75,000. Guess what, current Bitcoin price is $63,000+
40
$SLS Raises $150M! - Offering priced at $13/share - ~5.4% dilution - Stronger cash position for GPS commercialization Short-term pressure bearish, but long-term potential. 🚀
1
1
4
422
Bullish news for $IMRX: - Positive cancer research data - Astellas collaboration - faster than expected Phase 3 trial enrollment signal strong growth potential.
1
1
3
141
Recursion $RXRX announces FDA alignment on its Phase 3 trial design for AI-discovered REC-4881 targeting familial adenomatous polyposis (FAP), with the trial expected to begin in H2 2027.
1
96
Biogen $BIIB – Positive Alzheimer's Trial Results 🟢 Results: 38% slower clinical decline at 24 months, vs. 26% at 18 months. That's bullish and stronger efficacy supports Phase 3 development.
1
1
71